Generic Name and Formulations:
Polyethylene glycol (PEG) 3350; pwd for solution.
Indications for MIRALAX:
≥17yrs: Dissolve 17g in 4–8oz liquid and drink once daily for up to 7 days. May need 1–3 days for results.
<17yrs: not recommended.
Bowel obstruction (known or suspected).
Renal impairment: not recommended. Nausea, vomiting, abdominal pain or IBS: exclude bowel obstruction. Avoid prolonged, frequent, or excessive use. Pregnancy. Nursing mothers.
Loose, watery, frequent stools.
Powder—119g, 238g, 510g (w. measuring cap); Single-dose packets (17g)—10
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics